Roll-over Study to Allow Continued Access to Ribociclib

Running, not enrolling · Phase 4

Conditions studied: Metastatic Breast Cancer

In brief

The purpose of this study is to assess the long-term safety of ribociclib (LEE011) in combination with other drugs and provide post-trial access (PTA) to participants who are currently receiving treatment with ribociclib in combination with other drugs and continuing to have clinical benefit in a Novartis-sponsored global study that has reached its primary objective(s).

Key facts

Study ID
NCT05161195
Run by
Novartis Pharmaceuticals
People needed
134
Starts
2022-07-07
Expected to finish
2030-08-14
Last updated by the study team
2026-06-23

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.